Reviews Varenicline


No reviews yet.

Chantix Drug Description
CHANTIX®
(varenicline) Tablets

WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS
Serious neuropsychiatric events including, but not limited to, depression,
suicidal ideation, suicide attempt and completed suicide have been reported
in patients taking CHANTIX. Some reported cases may have been complicated by
the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed
mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal
ideation, has been reported in smokers undergoing a smoking cessation attempt
without medication. However, some of these symptoms have occurred in patients
taking CHANTIX who continued to smoke.
All patients being treated with CHANTIX should be observed for neuropsychiatric
symptoms including changes in behavior, hostility, agitation, depressed mood,
and suicide-related events, including ideation, behavior, and attempted suicide.
These symptoms, as well as worsening of pre-existing psychiatric illness and
completed suicide, have been reported in some patients attempting to quit smoking
while taking CHANTIX in the postmarketing experience. When symptoms were reported,
most were during CHANTIX treatment, but some were following discontinuation
of CHANTIX therapy.
These events have occurred in patients with and without preexisting psychiatric
disease. Patients with serious psychiatric illness such as schizophrenia, bipolar
disorder, and major depressive disorder did not participate in the premarketing
studies of CHANTIX, and the safety and efficacy of CHANTIX in such patients
has not been established.
Advise patients and caregivers that the patient should stop taking CHANTIX
and contact a healthcare provider immediately if agitation, hostility, depressed
mood, or changes in behavior or thinking that are not typical for the patient
are observed, or if the patient develops suicidal ideation or suicidal behavior.
In many postmarketing cases, resolution of symptoms after discontinuation of
CHANTIX was reported, although in some cases the symptoms persisted; therefore,
ongoing monitoring and supportive care should be provided until symptoms resolve.
The risks of CHANTIX should be weighed against the benefits of its use.
CHANTIX has been demonstrated to increase the likelihood of abstinence from
smoking for as long as one year compared to treatment with placebo. The health
benefits of quitting smoking are immediate and substantial. [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]

DRUG DESCRIPTION



What are the possible side effects of varenicline (Chantix)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any mood or behavior changes, or if you feel agitated, hostile, depressed, or have thoughts about suicide or hurting yourself.
Your family or other caregivers should also be alert to changes in your mood or behavior.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Chantix »




CHANTIX tablets contain varenicline (as the tartrate salt), which is a partial agonist selective for α4β2 nicotinic acetylcholine receptor subtypes.
Varenicline, as the tartrate salt, is a powder which is a white to off-white
to slightly yellow solid with the following chemical name: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-
h][3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1). It
is highly soluble in water. Varenicline tartrate has a molecular weight of 361.35
Daltons, and a molecular formula of C13H13N3•C4H6O6.
The chemical structure is:








CHANTIX is supplied for oral administration in two strengths: a 0.5 mg capsular
biconvex, white to off-white, film-coated tablet debossed with "Pfizer"
on one side and "CHX 0.5" on the other side and a 1 mg capsular biconvex,
light blue film-coated tablet debossed with "Pfizer" on one
side and "CHX 1.0" on the other side. Each 0.5 mg CHANTIX tablet contains
0.85 mg of varenicline tartrate equivalent to 0.5 mg of varenicline free base;
each 1mg CHANTIX tablet contains 1.71 mg of varenicline tartrate equivalent
to 1 mg of varenicline free base. The following inactive ingredients are included
in the tablets: microcrystalline cellulose, anhydrous dibasic calcium phosphate,
croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Opadry®
White (for 0.5 mg), Opadry® Blue (for 1 mg), and Opadry® Clear.
Last reviewed on RxList: 5/17/2010




Chantix Drug Description
CHANTIX®
(varenicline) Tablets

WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS
Serious neuropsychiatric events including, but not limited to, depression,
suicidal ideation, suicide attempt and completed suicide have been reported
in patients taking CHANTIX. Some reported cases may have been complicated by
the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed
mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal
ideation, has been reported in smokers undergoing a smoking cessation attempt
without medication. However, some of these symptoms have occurred in patients
taking CHANTIX who continued to smoke.
All patients being treated with CHANTIX should be observed for neuropsychiatric
symptoms including changes in behavior, hostility, agitation, depressed mood,
and suicide-related events, including ideation, behavior, and attempted suicide.
These symptoms, as well as worsening of pre-existing psychiatric illness and
completed suicide, have been reported in some patients attempting to quit smoking
while taking CHANTIX in the postmarketing experience. When symptoms were reported,
most were during CHANTIX treatment, but some were following discontinuation
of CHANTIX therapy.
These events have occurred in patients with and without preexisting psychiatric
disease. Patients with serious psychiatric illness such as schizophrenia, bipolar
disorder, and major depressive disorder did not participate in the premarketing
studies of CHANTIX, and the safety and efficacy of CHANTIX in such patients
has not been established.
Advise patients and caregivers that the patient should stop taking CHANTIX
and contact a healthcare provider immediately if agitation, hostility, depressed
mood, or changes in behavior or thinking that are not typical for the patient
are observed, or if the patient develops suicidal ideation or suicidal behavior.
In many postmarketing cases, resolution of symptoms after discontinuation of
CHANTIX was reported, although in some cases the symptoms persisted; therefore,
ongoing monitoring and supportive care should be provided until symptoms resolve.
The risks of CHANTIX should be weighed against the benefits of its use.
CHANTIX has been demonstrated to increase the likelihood of abstinence from
smoking for as long as one year compared to treatment with placebo. The health
benefits of quitting smoking are immediate and substantial. [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]

DRUG DESCRIPTION



What are the possible side effects of varenicline (Chantix)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any mood or behavior changes, or if you feel agitated, hostile, depressed, or have thoughts about suicide or hurting yourself.
Your family or other caregivers should also be alert to changes in your mood or behavior.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Chantix »




CHANTIX tablets contain varenicline (as the tartrate salt), which is a partial agonist selective for α4β2 nicotinic acetylcholine receptor subtypes.
Varenicline, as the tartrate salt, is a powder which is a white to off-white
to slightly yellow solid with the following chemical name: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-
h][3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1). It
is highly soluble in water. Varenicline tartrate has a molecular weight of 361.35
Daltons, and a molecular formula of C13H13N3•C4H6O6.
The chemical structure is:








CHANTIX is supplied for oral administration in two strengths: a 0.5 mg capsular
biconvex, white to off-white, film-coated tablet debossed with "Pfizer"
on one side and "CHX 0.5" on the other side and a 1 mg capsular biconvex,
light blue film-coated tablet debossed with "Pfizer" on one
side and "CHX 1.0" on the other side. Each 0.5 mg CHANTIX tablet contains
0.85 mg of varenicline tartrate equivalent to 0.5 mg of varenicline free base;
each 1mg CHANTIX tablet contains 1.71 mg of varenicline tartrate equivalent
to 1 mg of varenicline free base. The following inactive ingredients are included
in the tablets: microcrystalline cellulose, anhydrous dibasic calcium phosphate,
croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Opadry®
White (for 0.5 mg), Opadry® Blue (for 1 mg), and Opadry® Clear.
Last reviewed on RxList: 5/17/2010




Chantix Drug Description
CHANTIX®
(varenicline) Tablets

WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS
Serious neuropsychiatric events including, but not limited to, depression,
suicidal ideation, suicide attempt and completed suicide have been reported
in patients taking CHANTIX. Some reported cases may have been complicated by
the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed
mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal
ideation, has been reported in smokers undergoing a smoking cessation attempt
without medication. However, some of these symptoms have occurred in patients
taking CHANTIX who continued to smoke.
All patients being treated with CHANTIX should be observed for neuropsychiatric
symptoms including changes in behavior, hostility, agitation, depressed mood,
and suicide-related events, including ideation, behavior, and attempted suicide.
These symptoms, as well as worsening of pre-existing psychiatric illness and
completed suicide, have been reported in some patients attempting to quit smoking
while taking CHANTIX in the postmarketing experience. When symptoms were reported,
most were during CHANTIX treatment, but some were following discontinuation
of CHANTIX therapy.
These events have occurred in patients with and without preexisting psychiatric
disease. Patients with serious psychiatric illness such as schizophrenia, bipolar
disorder, and major depressive disorder did not participate in the premarketing
studies of CHANTIX, and the safety and efficacy of CHANTIX in such patients
has not been established.
Advise patients and caregivers that the patient should stop taking CHANTIX
and contact a healthcare provider immediately if agitation, hostility, depressed
mood, or changes in behavior or thinking that are not typical for the patient
are observed, or if the patient develops suicidal ideation or suicidal behavior.
In many postmarketing cases, resolution of symptoms after discontinuation of
CHANTIX was reported, although in some cases the symptoms persisted; therefore,
ongoing monitoring and supportive care should be provided until symptoms resolve.
The risks of CHANTIX should be weighed against the benefits of its use.
CHANTIX has been demonstrated to increase the likelihood of abstinence from
smoking for as long as one year compared to treatment with placebo. The health
benefits of quitting smoking are immediate and substantial. [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]

DRUG DESCRIPTION



What are the possible side effects of varenicline (Chantix)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any mood or behavior changes, or if you feel agitated, hostile, depressed, or have thoughts about suicide or hurting yourself.
Your family or other caregivers should also be alert to changes in your mood or behavior.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Chantix »




CHANTIX tablets contain varenicline (as the tartrate salt), which is a partial agonist selective for α4β2 nicotinic acetylcholine receptor subtypes.
Varenicline, as the tartrate salt, is a powder which is a white to off-white
to slightly yellow solid with the following chemical name: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-
h][3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1). It
is highly soluble in water. Varenicline tartrate has a molecular weight of 361.35
Daltons, and a molecular formula of C13H13N3•C4H6O6.
The chemical structure is:








CHANTIX is supplied for oral administration in two strengths: a 0.5 mg capsular
biconvex, white to off-white, film-coated tablet debossed with "Pfizer"
on one side and "CHX 0.5" on the other side and a 1 mg capsular biconvex,
light blue film-coated tablet debossed with "Pfizer" on one
side and "CHX 1.0" on the other side. Each 0.5 mg CHANTIX tablet contains
0.85 mg of varenicline tartrate equivalent to 0.5 mg of varenicline free base;
each 1mg CHANTIX tablet contains 1.71 mg of varenicline tartrate equivalent
to 1 mg of varenicline free base. The following inactive ingredients are included
in the tablets: microcrystalline cellulose, anhydrous dibasic calcium phosphate,
croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Opadry®
White (for 0.5 mg), Opadry® Blue (for 1 mg), and Opadry® Clear.
Last reviewed on RxList: 5/17/2010




Chantix Drug Description
CHANTIX®
(varenicline) Tablets

WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS
Serious neuropsychiatric events including, but not limited to, depression,
suicidal ideation, suicide attempt and completed suicide have been reported
in patients taking CHANTIX. Some reported cases may have been complicated by
the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed
mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal
ideation, has been reported in smokers undergoing a smoking cessation attempt
without medication. However, some of these symptoms have occurred in patients
taking CHANTIX who continued to smoke.
All patients being treated with CHANTIX should be observed for neuropsychiatric
symptoms including changes in behavior, hostility, agitation, depressed mood,
and suicide-related events, including ideation, behavior, and attempted suicide.
These symptoms, as well as worsening of pre-existing psychiatric illness and
completed suicide, have been reported in some patients attempting to quit smoking
while taking CHANTIX in the postmarketing experience. When symptoms were reported,
most were during CHANTIX treatment, but some were following discontinuation
of CHANTIX therapy.
These events have occurred in patients with and without preexisting psychiatric
disease. Patients with serious psychiatric illness such as schizophrenia, bipolar
disorder, and major depressive disorder did not participate in the premarketing
studies of CHANTIX, and the safety and efficacy of CHANTIX in such patients
has not been established.
Advise patients and caregivers that the patient should stop taking CHANTIX
and contact a healthcare provider immediately if agitation, hostility, depressed
mood, or changes in behavior or thinking that are not typical for the patient
are observed, or if the patient develops suicidal ideation or suicidal behavior.
In many postmarketing cases, resolution of symptoms after discontinuation of
CHANTIX was reported, although in some cases the symptoms persisted; therefore,
ongoing monitoring and supportive care should be provided until symptoms resolve.
The risks of CHANTIX should be weighed against the benefits of its use.
CHANTIX has been demonstrated to increase the likelihood of abstinence from
smoking for as long as one year compared to treatment with placebo. The health
benefits of quitting smoking are immediate and substantial. [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]

DRUG DESCRIPTION



What are the possible side effects of varenicline (Chantix)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any mood or behavior changes, or if you feel agitated, hostile, depressed, or have thoughts about suicide or hurting yourself.
Your family or other caregivers should also be alert to changes in your mood or behavior.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Chantix »




CHANTIX tablets contain varenicline (as the tartrate salt), which is a partial agonist selective for α4β2 nicotinic acetylcholine receptor subtypes.
Varenicline, as the tartrate salt, is a powder which is a white to off-white
to slightly yellow solid with the following chemical name: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-
h][3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1). It
is highly soluble in water. Varenicline tartrate has a molecular weight of 361.35
Daltons, and a molecular formula of C13H13N3•C4H6O6.
The chemical structure is:








CHANTIX is supplied for oral administration in two strengths: a 0.5 mg capsular
biconvex, white to off-white, film-coated tablet debossed with "Pfizer"
on one side and "CHX 0.5" on the other side and a 1 mg capsular biconvex,
light blue film-coated tablet debossed with "Pfizer" on one
side and "CHX 1.0" on the other side. Each 0.5 mg CHANTIX tablet contains
0.85 mg of varenicline tartrate equivalent to 0.5 mg of varenicline free base;
each 1mg CHANTIX tablet contains 1.71 mg of varenicline tartrate equivalent
to 1 mg of varenicline free base. The following inactive ingredients are included
in the tablets: microcrystalline cellulose, anhydrous dibasic calcium phosphate,
croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Opadry®
White (for 0.5 mg), Opadry® Blue (for 1 mg), and Opadry® Clear.
Last reviewed on RxList: 5/17/2010




Chantix Drug Description
CHANTIX®
(varenicline) Tablets

WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS
Serious neuropsychiatric events including, but not limited to, depression,
suicidal ideation, suicide attempt and completed suicide have been reported
in patients taking CHANTIX. Some reported cases may have been complicated by
the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed
mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal
ideation, has been reported in smokers undergoing a smoking cessation attempt
without medication. However, some of these symptoms have occurred in patients
taking CHANTIX who continued to smoke.
All patients being treated with CHANTIX should be observed for neuropsychiatric
symptoms including changes in behavior, hostility, agitation, depressed mood,
and suicide-related events, including ideation, behavior, and attempted suicide.
These symptoms, as well as worsening of pre-existing psychiatric illness and
completed suicide, have been reported in some patients attempting to quit smoking
while taking CHANTIX in the postmarketing experience. When symptoms were reported,
most were during CHANTIX treatment, but some were following discontinuation
of CHANTIX therapy.
These events have occurred in patients with and without preexisting psychiatric
disease. Patients with serious psychiatric illness such as schizophrenia, bipolar
disorder, and major depressive disorder did not participate in the premarketing
studies of CHANTIX, and the safety and efficacy of CHANTIX in such patients
has not been established.
Advise patients and caregivers that the patient should stop taking CHANTIX
and contact a healthcare provider immediately if agitation, hostility, depressed
mood, or changes in behavior or thinking that are not typical for the patient
are observed, or if the patient develops suicidal ideation or suicidal behavior.
In many postmarketing cases, resolution of symptoms after discontinuation of
CHANTIX was reported, although in some cases the symptoms persisted; therefore,
ongoing monitoring and supportive care should be provided until symptoms resolve.
The risks of CHANTIX should be weighed against the benefits of its use.
CHANTIX has been demonstrated to increase the likelihood of abstinence from
smoking for as long as one year compared to treatment with placebo. The health
benefits of quitting smoking are immediate and substantial. [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]

DRUG DESCRIPTION



What are the possible side effects of varenicline (Chantix)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any mood or behavior changes, or if you feel agitated, hostile, depressed, or have thoughts about suicide or hurting yourself.
Your family or other caregivers should also be alert to changes in your mood or behavior.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Chantix »




CHANTIX tablets contain varenicline (as the tartrate salt), which is a partial agonist selective for α4β2 nicotinic acetylcholine receptor subtypes.
Varenicline, as the tartrate salt, is a powder which is a white to off-white
to slightly yellow solid with the following chemical name: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-
h][3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1). It
is highly soluble in water. Varenicline tartrate has a molecular weight of 361.35
Daltons, and a molecular formula of C13H13N3•C4H6O6.
The chemical structure is:








CHANTIX is supplied for oral administration in two strengths: a 0.5 mg capsular
biconvex, white to off-white, film-coated tablet debossed with "Pfizer"
on one side and "CHX 0.5" on the other side and a 1 mg capsular biconvex,
light blue film-coated tablet debossed with "Pfizer" on one
side and "CHX 1.0" on the other side. Each 0.5 mg CHANTIX tablet contains
0.85 mg of varenicline tartrate equivalent to 0.5 mg of varenicline free base;
each 1mg CHANTIX tablet contains 1.71 mg of varenicline tartrate equivalent
to 1 mg of varenicline free base. The following inactive ingredients are included
in the tablets: microcrystalline cellulose, anhydrous dibasic calcium phosphate,
croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Opadry®
White (for 0.5 mg), Opadry® Blue (for 1 mg), and Opadry® Clear.
Last reviewed on RxList: 5/17/2010





Other reviews about Varenicline on wordpress

Varenicline Tablets May Be Linked to Risk for Serious Neuropsychiatric Symptoms
  by pchalita
Yael Waknine Medscape Medical News 2008. © 2008 Medscape February 2, 2008 — The prescribing information for varenicline tablets […]


CHANTIX® (varenicline)
  by kanlayanee
[caption id="" align="alignnone" width="215" caption="Chantix™"][/caption] Varenicline (trade name Chantix in the USA and Champix in Europe and other countries, marketed by Pfizer, usually in the form of varenicline tartrate) […]


Study suggests that varenicline may help regular drinkers consume less alcohol.
  by abrandemihl
Time (3/8, Cloud) reported that, according to a study published in the journal Biological Psychiatry, Chantix (varenicline) "has...helped a group of regular drinkers consume less alcohol." For the […]


FDA MedWatch - Varenicline (Chantix) and Bupropion (Zyban, Wellbutrin, and generics)
  by irbtipoftheweek
FDA notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed […]


Comment on FDA Advisory on varenicline and bupropion
  by heremias
In my previous post I summarized the new information from FDA on varenicline and bupropion for smoking cessation. Before giving my opinion on this, there are a couple […]


Study Counters Warnings on Quit-Smoking Drug
  by timeinctemp
FRIDAY, Oct. 2 (HealthDay News) — The smoking cessation drug varenicline (Chantix) does not increase the risk for self-harm or depression, according to a new British study. In July, […]


Varenicline ( Chantix ) does not produce depression or suicide: new study
  by heremias
The smoking cessation medicine, varenicline, has proven safe and effective in numerous placebo-controlled trials, but in the post-marketing phase there were numerous reports of patients experiencing “neuropsychiatric effects” […]


Researchers find no clear evidence for self-harm, suicidal thoughts in patients taking varenicline.
  by abrandemihl
 (10/1, Boyles) reported that, according to a study published Oct. 1 in BMJ Online First, the risk of "suicide and suicidal thoughts" associated with the antismoking medication Chantix […]


Chantix Varenicline for Smoking Cessation Treatment
  by wangxixi
by Aaron Edwards Chantix Varenicline for Smoking Cessation Treatment Chantix Varenicline The reasons you started smoking […]


Best Quit Smoking Aids - Quit Aids - Smoking Cessation Aids
  by wangxixi
bestquitsmokingaids.wordpress.com Smoking cessation is a serious thing, You should seek and get all of the quit smoking support to quit smoking. Here is a Quit Smoking Aid Guide […]



Other reviews about Varenicline on web:

Varenicline (trade name Chantix in the USA and Champix in Europe and other countries, marketed by Pfizer, usually in the form of varenicline tartrate) is a prescription ... Varenicline - Wikipedia, the free encyclopedia


Physician reviewed varenicline patient information - includes varenicline description, dosage and directions. varenicline medical facts from Drugs.com


Varenicline Brand names: Chantix™ Drug Forms: Varenicline tablets (below) Varenicline tartrate Oral tablet Varenicline tartrate Oral tablet, Varenicline: Information from Answers.com


All about Varenicline. View complete and up to date Varenicline information - part of the Drugs.com trusted medication database. Varenicline Facts and Comparisons at Drugs.com


Features information about dosage, usage, warnings, and side effects. Varenicline: MedlinePlus Drug Information


Find out why quitting smoking with CHANTIX can be different. Quitting – CHANTIX Official Site – CHANTIX is a Prescription ...


Varenicline - Chantix Introduction. Varenicline Tartrate is the generic drug used as the active ingredient for the anti-smoking medication branded as Chantix. Buy Varenicline Tartrate - Generic Chantix Champix to stop smoking ...


"were no significant differences" between Chantix and nicotine patch users at either 6 months (varenicline 38.6% vs. patch 34.1%) or one year (varenicline 34.8% vs. patch 31.4%). Will Chantix really help me quit smoking? It's unlikely!


Learn more about Varenicline. Find the Web's best health guides, medical reports, news, videos and tools for Varenicline. Share Varenicline experiences and get advice from experts. Varenicline Overview - References, Advice, News, Videos, Coping ...


Learn about the prescription medication Chantix (Varenicline), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Chantix (Varenicline) Drug Information: Uses, Side Effects, Drug ...





Featured Reviews

Reviews Clobetasol Propionate Foam

Olux-E Drug Description Olux-E™ (clobetasol propionate) Foam, 0.05% Rx Only For Topical Use Only Not for Ophthalmic, Oral, or Intravaginal Use DRUG DESCRIPTION What are the possible side effects of clobetasol...
Read More  |  Review This
Reviews Somatropin

Nutropin AQ Drug Description Nutropin AQ® [somatropin (rDNA origin)] Injection DRUG DESCRIPTION What are the possible side effects of somatropin? If you have Prader-Willi syndrome, call your doctor promptly if you develop signs...
Read More  |  Review This
Reviews Abacavir Sulfate, Lamivudine, and Zidovudine

Trizivir Drug Description TRIZIVIR® (abacavir sulfate, lamivudine, and zidovudine) Tablets WARNINGS TRIZIVIR contains 3 nucleoside analogues (abacavir sulfate, lamivudine, and zidovudine) and is intended only for patients...
Read More  |  Review This
Reviews Nafcillin Injection

Nafcillin Injection Drug Description Nafcillin Injection, USP in PL 2040 Plastic Container For Intravenous Use Only GALAXY Container (PL 2040 Plastic) To reduce the development of drug-resistant bacteria and maintain the effectiveness...
Read More  |  Review This
Reviews Exelon

Exelon Drug Description Exelon® (rivastigmine tartrate) Capsules and Oral Solution DRUG DESCRIPTION What are the possible side effects of rivastigmine (Exelon)? Get emergency medical help if you have any of these signs of an...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....